177 related articles for article (PubMed ID: 10513984)
1. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
Xu X; Shen J; Mall JW; Myers JA; Huang W; Blinder L; Saclarides TJ; Williams JW; Chong AS
Biochem Pharmacol; 1999 Nov; 58(9):1405-13. PubMed ID: 10513984
[TBL] [Abstract][Full Text] [Related]
2. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
3. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation.
Xu X; Williams JW; Gong H; Finnegan A; Chong AS
Biochem Pharmacol; 1996 Aug; 52(4):527-34. PubMed ID: 8759024
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.
Mattar T; Kochhar K; Bartlett R; Bremer EG; Finnegan A
FEBS Lett; 1993 Nov; 334(2):161-4. PubMed ID: 8224241
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.
Doscas ME; Williamson AJ; Usha L; Bogachkov Y; Rao GS; Xiao F; Wang Y; Ruby C; Kaufman H; Zhou J; Williams JW; Li Y; Xu X
Neoplasia; 2014 Oct; 16(10):824-34. PubMed ID: 25379019
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
Nair RV; Cao W; Morris RE
Immunol Lett; 1995 Dec; 48(2):77-80. PubMed ID: 8719103
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
[TBL] [Abstract][Full Text] [Related]
10. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms.
Elder RT; Xu X; Williams JW; Gong H; Finnegan A; Chong AS
J Immunol; 1997 Jul; 159(1):22-7. PubMed ID: 9200434
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
Nair RV; Cao W; Morris RE
Immunol Lett; 1995 Sep; 47(3):171-4. PubMed ID: 8747714
[TBL] [Abstract][Full Text] [Related]
12. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
Li Y; Yi L; Cheng S; Wang Y; Wang J; Sun J; Zhang Q; Xu X
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416466
[TBL] [Abstract][Full Text] [Related]
14. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
Sawamukai N; Saito K; Yamaoka K; Nakayamada S; Ra C; Tanaka Y
J Immunol; 2007 Nov; 179(10):6479-84. PubMed ID: 17982036
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
16. Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide.
Mirmohammadsadegh A; Homey B; Abts HF; Köhrer K; Ruzicka T; Michel G
Biochem Pharmacol; 1998 May; 55(9):1523-9. PubMed ID: 10076546
[TBL] [Abstract][Full Text] [Related]
17. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production.
Siemasko K; Chong AS; Jäck HM; Gong H; Williams JW; Finnegan A
J Immunol; 1998 Feb; 160(4):1581-8. PubMed ID: 9469413
[TBL] [Abstract][Full Text] [Related]
19. Leflunomide interferes with pyrimidine nucleotide biosynthesis.
Cherwinski HM; Byars N; Ballaron SJ; Nakano GM; Young JM; Ransom JT
Inflamm Res; 1995 Aug; 44(8):317-22. PubMed ID: 8581517
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay.
Slauson SD; Silva HT; Sherwood SW; Morris RE
Immunol Lett; 1999 Apr; 67(3):179-83. PubMed ID: 10369124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
